CVAC CureVac
- 3.420
- +0.100+3.01%
CureVac News
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | 6-K: Report of foreign private issuer (related to financial reporting)
CureVac | 6-K: Report of foreign private issuer (related to financial reporting)
CureVac | 20-F: FY2023 Annual Report
CureVac | 6-K: Report of foreign private issuer (related to financial reporting)
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | 144: Notice of proposed sale of securities pursuant to Rule 144
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(1.2%),Peter Kolchinsky(1.2%), etc.
CureVac | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-GSK plc(7.4%)
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
CureVac | 144: Notice of proposed sale of securities pursuant to Rule 144
Analysis
Price Target
No Data
